{
  "@context": "https://schema.org",
  "name": "BioVertex Consulting services",
  "url": "https://www.biovertexconsulting.com/services",
  "provider": {
    "name": "BioVertex Consulting LLP",
    "url": "https://www.biovertexconsulting.com",
    "email": "contactus@biovertexconsulting.com"
  },
  "services": [
    {
      "name": "Strategy & Planning",
      "slug": "strategy-and-planning",
      "url": "https://www.biovertexconsulting.com/services/strategy-and-planning",
      "description": "Target Product Profile, development roadmaps, competitive intelligence, and business development for biotech, pharma, and medtech. Pre-Seed through clinic.",
      "audience": "Founders, scientific founders spinning out of academia, and CEOs preparing a Seed or Series A package."
    },
    {
      "name": "Portfolio, Program & Alliance Management",
      "slug": "program-management",
      "url": "https://www.biovertexconsulting.com/services/program-management",
      "description": "Integrated timelines, stage-gate governance, KPI monitoring, board reporting, and alliance management for biotech and pharma programs. CMC through clinic.",
      "audience": "Early-stage biotechs, pharma teams that need surge capacity, and VCs who need portfolio companies to execute after close."
    },
    {
      "name": "Process Optimization & Standardization",
      "slug": "process-optimization",
      "url": "https://www.biovertexconsulting.com/services/process-optimization",
      "description": "Decision frameworks, SOPs, knowledge management, and operational standards for life sciences companies moving from founder-led to investable organizations.",
      "audience": "Teams that have outgrown Slack-as-a-system and VCs who need comparable reporting across a portfolio."
    },
    {
      "name": "Scientific & Regulatory Communications",
      "slug": "scientific-communications",
      "url": "https://www.biovertexconsulting.com/services/scientific-communications",
      "description": "Scientific communication plans, regulatory writing support, publication strategy, and investor-ready narratives for biotech and pharma.",
      "audience": "Companies approaching IND, partnering, or a priced round, and teams that need medical writing depth without a full-time function."
    },
    {
      "name": "Team & Operations Management",
      "slug": "team-and-operations",
      "url": "https://www.biovertexconsulting.com/services/team-and-operations",
      "description": "Cross-functional team management, charters, RACI, and drug-development coaching for biotech founders and academic groups entering industry.",
      "audience": "Founders hiring their first operators, academic groups commercializing, and CEOs who need the team to run without them in every meeting."
    },
    {
      "name": "Fractional & Interim Leadership",
      "slug": "fractional-leadership",
      "url": "https://www.biovertexconsulting.com/services/fractional-leadership",
      "description": "Fractional Head of Program Management, VP of Operations/Strategy, and interim Chief of Staff for biotech CEOs. Embedded in days, scoped to runway.",
      "audience": "CEOs who need an operator now, boards that will not fund a C-level yet, and VCs placing leadership into a portfolio company post-close."
    },
    {
      "name": "VC Due Diligence & Portfolio Support",
      "slug": "vc-due-diligence",
      "url": "https://www.biovertexconsulting.com/venture-capital",
      "description": "Pre-investment operational due diligence, post-close portfolio buildout, cross-portfolio standardization, and board-ready reporting for life sciences VC firms.",
      "audience": "Life sciences venture capital firms and their portfolio companies."
    }
  ]
}